Overview
The company's platforms—Allo-Glue™, A-Kine®, and multimodal cell engagers—work by connecting proteins on and within cells to target cancer through the body's natural defense mechanisms. Orionis focuses on precision targeting to harness immune signaling while minimizing off-target effects.
Key people
In the news
Something wrong or missing? Send an update. Fixed within 24 hours.